PT  - JOURNAL ARTICLE
AU  - TAKASHI SHINTANI
AU  - YUKINORI MATSUO
AU  - YUSUKE IIZUKA
AU  - TAKAMASA MITSUYOSHI
AU  - TAKASHI MIZOWAKI
AU  - MASAHIRO HIRAOKA
TI  - Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy
DP  - 2017 Sep 01
TA  - Anticancer Research
PG  - 5161--5167
VI  - 37
IP  - 9
4099  - http://ar.iiarjournals.org/content/37/9/5161.short
4100  - http://ar.iiarjournals.org/content/37/9/5161.full
SO  - Anticancer Res2017 Sep 01; 37
AB  - Background/Aim: To examine the prognostic significance of serum carcinoembryonic antigen (CEA) for stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). Patients and Methods: In total, 129 stage I NSCLC patients were analyzed and divided into two groups: CEA-High (CEA>5 ng/ml) and CEA-Low (CEA≤5 ng/ml). Results: Median follow-up time was 38 months. Overall survival was not significantly different between CEA-High (n=47) and CEA-Low (n=82) patients (57% vs. 63% at 3 years; p=0.39), although progression-free survival (PFS) was significantly worse in CEA-High patients (31% vs. 51% at 3 years; p=0.01). Larger tumor size and high CEA level were independent prognostic factors for worse PFS. Failure pattern analysis showed that regional node or distant recurrence was more common in CEA-High patients (47%) than in CEA-Low patients (29%). Conclusion: Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully.